Circulation:对于心力衰竭患者,合并肺动脉高压可促进其整体肺血管重构

2018-04-24 MedSci MedSci原创

Ahmed U. Fayyaz等人推测心力衰竭(HF)时肺静脉高压可导致肺静脉重构,而静脉重构的严重程度与HF时的肺动脉高压的严重程度相关。本研究共纳入108位合并PH(肺动脉收缩压[PASP]≥40mmHg)的HF患者(HF-PH;55位射血分数降低)和12位正常对照以及17位原发性肺静脉闭塞性疾病(PVOD)患者。通过活检(对照、HF-PH、7位PVOD)或手术(10位PVOD)获取肺组织样本

Ahmed U. Fayyaz等人推测心力衰竭(HF)时肺静脉高压可导致肺静脉重构,而静脉重构的严重程度与HF时的肺动脉高压的严重程度相关。

本研究共纳入108位合并PH(肺动脉收缩压[PASP]≥40mmHg)的HF患者(HF-PH;55位射血分数降低)和12位正常对照以及17位原发性肺静脉闭塞性疾病(PVOD)患者。通过活检(对照、HF-PH、7位PVOD)或手术(10位PVOD)获取肺组织样本,对样本的所有可分析的动脉(4949个)、静脉(7630)和不确定的小血管(IV,2168)进行定量组织形态检测以确定中肌层(动脉)和内膜(% IT)(动脉、静脉和IV)厚度相比血管直径的百分比。

HF-PH组的动脉中肌层的平均百分比(对照 6.9、HF-PH 11.0、PVOD 15.0)、动脉%IT(4.9、14.0、31.1)和IV %IT(10.6、25.8、50.0)均高于对照组(p均<0.0001),但低于PVOD组(p均≤0.005)。HF-PH组的PASP(mmHg)低于PVOD组(中位值 59[50-70] vs 91[82-103])。PASP与动脉内膜厚度百分比(r=0.41)和动脉%IT(r=0.35)相关,但与静脉 %IT(r=0.49)和IV % IT(r=0.55)的关联性更强(p均<0.0001)。根据动脉内膜厚度百分比和%IT校正后,PASP与静脉或IV %IT仍有显着关联,并且跟HF类型无关。在右心置管的患者(HF-PH 20位、PVOD 14位)中,跨肺压与肺血管重构之间存在类似的相关性,而且比静脉和IV %IT间的关联在数值上更强。尽管在右心室功能不全的HF-PH患者中,PASP稍高,但肺血管重构并不会更严重。肺血管重构的严重程度与肺弥散能力减退相关。

对于心衰患者,PH与整体肺血管重构相关,但PH的严重程度与静脉和小IV内膜厚度的关系更为明显,类似于在PVOD患者中观察到的现象。本研究发现拓展了我们对心衰患者肺动脉高压的病理生理的了解。

原始出处:

Ahmed U. Fayyaz,et al. Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation. April 24,2018.https://doi.org/10.1161/CIRCULATIONAHA.117.031608

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650559, encodeId=869216505599d, content=<a href='/topic/show?id=c6c389e99a3' target=_blank style='color:#2F92EE;'>#血管重构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89799, encryptionId=c6c389e99a3, topicName=血管重构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4db324029989, createdName=tonychen29, createdTime=Tue Jul 31 03:12:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925229, encodeId=9ae8192522970, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 22 20:12:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050792, encodeId=9cc61050e92e4, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Tue Apr 24 14:12:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308853, encodeId=4af7308853ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Apr 24 12:22:10 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308849, encodeId=de9c308849b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Apr 24 12:17:02 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308840, encodeId=f91630884050, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Apr 24 12:09:59 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308832, encodeId=bf9a30883204, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Apr 24 11:26:27 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650559, encodeId=869216505599d, content=<a href='/topic/show?id=c6c389e99a3' target=_blank style='color:#2F92EE;'>#血管重构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89799, encryptionId=c6c389e99a3, topicName=血管重构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4db324029989, createdName=tonychen29, createdTime=Tue Jul 31 03:12:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925229, encodeId=9ae8192522970, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 22 20:12:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050792, encodeId=9cc61050e92e4, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Tue Apr 24 14:12:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308853, encodeId=4af7308853ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Apr 24 12:22:10 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308849, encodeId=de9c308849b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Apr 24 12:17:02 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308840, encodeId=f91630884050, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Apr 24 12:09:59 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308832, encodeId=bf9a30883204, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Apr 24 11:26:27 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650559, encodeId=869216505599d, content=<a href='/topic/show?id=c6c389e99a3' target=_blank style='color:#2F92EE;'>#血管重构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89799, encryptionId=c6c389e99a3, topicName=血管重构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4db324029989, createdName=tonychen29, createdTime=Tue Jul 31 03:12:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925229, encodeId=9ae8192522970, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 22 20:12:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050792, encodeId=9cc61050e92e4, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Tue Apr 24 14:12:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308853, encodeId=4af7308853ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Apr 24 12:22:10 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308849, encodeId=de9c308849b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Apr 24 12:17:02 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308840, encodeId=f91630884050, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Apr 24 12:09:59 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308832, encodeId=bf9a30883204, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Apr 24 11:26:27 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-04-24 明天jing

    肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1650559, encodeId=869216505599d, content=<a href='/topic/show?id=c6c389e99a3' target=_blank style='color:#2F92EE;'>#血管重构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89799, encryptionId=c6c389e99a3, topicName=血管重构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4db324029989, createdName=tonychen29, createdTime=Tue Jul 31 03:12:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925229, encodeId=9ae8192522970, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 22 20:12:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050792, encodeId=9cc61050e92e4, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Tue Apr 24 14:12:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308853, encodeId=4af7308853ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Apr 24 12:22:10 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308849, encodeId=de9c308849b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Apr 24 12:17:02 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308840, encodeId=f91630884050, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Apr 24 12:09:59 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308832, encodeId=bf9a30883204, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Apr 24 11:26:27 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-04-24 183****7028

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1650559, encodeId=869216505599d, content=<a href='/topic/show?id=c6c389e99a3' target=_blank style='color:#2F92EE;'>#血管重构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89799, encryptionId=c6c389e99a3, topicName=血管重构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4db324029989, createdName=tonychen29, createdTime=Tue Jul 31 03:12:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925229, encodeId=9ae8192522970, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 22 20:12:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050792, encodeId=9cc61050e92e4, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Tue Apr 24 14:12:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308853, encodeId=4af7308853ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Apr 24 12:22:10 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308849, encodeId=de9c308849b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Apr 24 12:17:02 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308840, encodeId=f91630884050, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Apr 24 12:09:59 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308832, encodeId=bf9a30883204, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Apr 24 11:26:27 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-04-24 131****1460

    学习了受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1650559, encodeId=869216505599d, content=<a href='/topic/show?id=c6c389e99a3' target=_blank style='color:#2F92EE;'>#血管重构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89799, encryptionId=c6c389e99a3, topicName=血管重构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4db324029989, createdName=tonychen29, createdTime=Tue Jul 31 03:12:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925229, encodeId=9ae8192522970, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 22 20:12:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050792, encodeId=9cc61050e92e4, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Tue Apr 24 14:12:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308853, encodeId=4af7308853ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Apr 24 12:22:10 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308849, encodeId=de9c308849b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Apr 24 12:17:02 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308840, encodeId=f91630884050, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Apr 24 12:09:59 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308832, encodeId=bf9a30883204, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Apr 24 11:26:27 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-04-24 惠映实验室

    学习了.谢谢分享.

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1650559, encodeId=869216505599d, content=<a href='/topic/show?id=c6c389e99a3' target=_blank style='color:#2F92EE;'>#血管重构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89799, encryptionId=c6c389e99a3, topicName=血管重构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4db324029989, createdName=tonychen29, createdTime=Tue Jul 31 03:12:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925229, encodeId=9ae8192522970, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 22 20:12:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050792, encodeId=9cc61050e92e4, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Tue Apr 24 14:12:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308853, encodeId=4af7308853ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Apr 24 12:22:10 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308849, encodeId=de9c308849b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Apr 24 12:17:02 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308840, encodeId=f91630884050, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Apr 24 12:09:59 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308832, encodeId=bf9a30883204, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Apr 24 11:26:27 CST 2018, time=2018-04-24, status=1, ipAttribution=)]
    2018-04-24 smartxiuxiu

    不错的文章

    0

相关资讯

Eur Heart J:西地那非不能改善心脏瓣膜置换术后持续性肺动脉高压患者预后

本研究的目的旨在探究西地那非是否能改善心脏瓣膜疾病(VHD)矫正后持续性肺动脉高压患者的预后。本次多中心随机双盲对照临床研究纳入了200名1年前接受过心脏瓣膜置换术且平均肺动脉压力≥30mmHg的成年患者,其中104名患者接受了西地那非治疗,96名患者接受了安慰剂治疗,时间长达6个月,主要终点事件是死亡、心衰入院、功能分级改变和患者自我评估的临床综合评分。分析结果显示,西地那非组仅27名患者的临床

这种病不常见 极易误诊为特发性肺动脉高压

患者,女,34岁。既往有较大活动后气短、胸闷史,未予以重视。6个月前出现间断咯血,无发热,被当地医院诊断为肺动脉高压。患者既往有反复鼻出血史;反复黑便,贫血。其父亲及一姐均有反复鼻出血史。患者肺动脉高压到底是何种疾病引起?是特发性肺动脉高压吗?详见以下病例。

2018CCCP&SCC丨肺动脉高压临床难发现的重度病变——丛状病变的病理研究进展

丛状病变(Plexiform lesions,PLs)是动脉型肺动脉高压(Pulmonary Arterial Hypertension,PAH)中不可逆的晚期重度病变,是先天性心血管病(先心病)矫正手术或介入封堵手术的禁忌证。然而,现临床检查和实验室检查均很难发现PLs,易造成术后人财两空。这是国内外临床医学尚未解决的重要课题。从阜外医院和华信医院特发性PAH(IPAH)尸检8例、先天心肺血管病

JAHA:肺动脉高压儿童和青年人心导管检查主要早期不良事件的危险因素!

由此可见,青年PH患者是诊断性和介入性心导管检查的高危人群。医院处理PH的经验与与降低的风险相关,独立于总的心导管病例数量。

Eur J Cardio-Thorac Surg:肺动脉高压是否应作为肺减容术的禁忌症?

一直以来肺动脉高压(PH)被认为是肺减容术(LVRS)的禁忌症。因为,有研究认为支气管镜下肺减容术并不会增加肺气肿合并PH患者的死亡率。来自瑞士的Claudio Caviezel教授等为了评估了PH对接受LVRS患者预后的影响,开展了一项研究,研究结果发表在近期的EJCTS杂志上。

JACC:肺动脉高压相关发病率与患者的死亡风险呈明显相关

一般认为,疾病进展过程中出现肺动脉高压(PAH)是预后不好的征兆,然而,PAH相关发病率与预后的相关性没有在随机临床对照试验中证实。本研究的目的旨在用SERAPHIN 和GRIPHON临床研究的数据评估PAH发病事件对后续死亡风险的影响。在SERAPHIN研究中,出现有PAH事件患者3个月的死亡率要高于无PAH事件患者([HR]: 3.39; 95% [CI]: 1.94-5.92)。在GRIPH